Optimization of [¹⁸F]-FDOPA Brain PET Acquisition Times for Assessment of Parkinsonism in the Clinical Setting

References

1. 1.↵
   1. Franceschi AM,
   2. Franceschi D

   1. Ponisio MR,
   2. Iranpour P,
   3. Benzinger T

   . FDOPA in Movement Disorders and Neuro-Oncology. In: Franceschi AM, Franceschi D. eds. Hybrid PET/MR Neuroimaging: A Comprehensive Approach. Springer-Verlag; 2022:121–35
2. 2.↵
   1. Eshuis SA,
   2. Jager PL,
   3. Maguire RP, et al

   . Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging 2009;36:454–62 doi:10.1007/s00259-008-0989-5 pmid:19037637

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Chondrogiannis S,
   2. Marzola MC,
   3. Al-Nahhas A, et al

   . Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun 2013;34:1141–49 doi:10.1097/MNM.0000000000000008 pmid:24128899

   CrossRefPubMed
4. 4.↵
   1. Buu NT

   . Vesicular accumulation of dopamine following L-DOPA administration. Biochem Pharmacol 1989;38:1787–92 doi:10.1016/0006-2952(89)90413-9 pmid:2735936

   CrossRefPubMed
5. 5.↵
   1. Lee CS,
   2. Samii A,
   3. Sossi V, et al

   . In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol 2000;47:493–503 doi:10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4 pmid:10762161

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Morrish PK,
   2. Sawle GV,
   3. Brooks DJ

   . An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 1996;119(Pt 2):585–91 doi:10.1093/brain/119.2.585 pmid:8800950

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Leenders KL,
   2. Salmon EP,
   3. Tyrrell P, et al

   . The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease. Arch Neurol 1990;47:1290–98 doi:10.1001/archneur.1990.00530120034007 pmid:2123623

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Bruck A,
   2. Aalto S,
   3. Rauhala E, et al

   . A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease shows nonlinear progression in the putamen. Mov Disord 2009;24:1009–15 doi:10.1002/mds.22484 pmid:19260097

   CrossRefPubMed
9. 9.↵
   1. Calabria FF,
   2. Calabria E,
   3. Gangemi V, et al

   . Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders. Hell J Nucl Med 2016;19:33–41 doi:10.1967/s002449910335 pmid:26929938

   CrossRefPubMed
10. 10.↵
    1. Kaasinen V,
    2. Vahlberg T

    . Striatal dopamine in Parkinson disease: a meta-analysis of imaging studies. Ann Neurol 2017;82:873–82 doi:10.1002/ana.25103 pmid:29165839

    CrossRefPubMed
11. 11.↵
    1. Ghaemi M,
    2. Raethjen J,
    3. Hilker R, et al

    . Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study. Mov Disord 2002;17:782–88 doi:10.1002/mds.10125 pmid:12210876

    CrossRefPubMed
12. 12.↵
    1. Broussolle E,
    2. Dentresangle C,
    3. Landais P, et al

    . The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease. J Neurol Sci 1999;166:141–51 doi:10.1016/s0022-510x(99)00127-6 pmid:10475108

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Eidelberg D,
    2. Moeller JR,
    3. Dhawan V, et al

    . The metabolic anatomy of Parkinson’s disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203–13 doi:10.1002/mds.870050304 pmid:2117706

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Vingerhoets FJ,
    2. Schulzer M,
    3. Calne DB, et al

    . Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58–64 doi:10.1002/ana.410410111 pmid:9005866

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Otsuka M,
    2. Ichiya Y,
    3. Kuwabara Y, et al

    . Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson’s disease: correlations with the three main symptoms. J Neurol Sci 1996;136:169–73 doi:10.1016/0022-510x(95)00316-t pmid:8815166

    CrossRefPubMedWeb of Science
16. 16.↵
    Food and Drug Administration. Drug Trials Snapshots: Fluorodopa F 18. https://www.fda.gov/drugs/drug-trials-snapshots-fluorodopa-f-18. Accessed: July 7, 2023
17. 17.↵
    Centers for Medicare and Medicaid Services. Billing and Coding: Positron Emission Tomography Scans Coverage. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=54666. Accessed July 7, 2023
18. 18.↵
    Food and Drug Administration. Highlights of Prescribing Information. October 22, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200655s000lbl.pdf. Accessed: July 7, 2023
19. 19.↵
    1. Ishikawa T,
    2. Dhawan V,
    3. Kazumata K, et al

    . Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760–65 pmid:8917170

    Abstract/FREE Full Text
20. 20.↵
    1. Dhawan V,
    2. Ishikawa T,
    3. Patlak C, et al

    . Combined FDOPA and 3OMFD PET studies in Parkinson's disease. J Nucl Med 1996;37:209–16 pmid:8917170

    Abstract/FREE Full Text
21. 21.↵
    Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-fluorodopa-f-18. Accessed: March 21, 2024
22. 22.↵
    1. Morbelli S,
    2. Esposito G,
    3. Arbizu J, et al

    . EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging 2020;47:1885–912 doi:10.1007/s00259-020-04817-8 pmid:32388612

    CrossRefPubMed
23. 23.↵
    1. Benamer TS,
    2. Patterson J,
    3. Grosset DG, et al

    . Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503–10 doi:10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Booij J,
    2. Hemelaar TG,
    3. Speelman JD, et al

    . One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med 1999;40:753–61 pmid:10319746

    Abstract/FREE Full Text
25. 25.↵
    1. Scherfler C,
    2. Schwarz J,
    3. Antonini A, et al

    . Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007;22:1229–38 doi:10.1002/mds.21505 pmid:17486648

    CrossRefPubMed
26. 26.↵
    1. Nicastro N,
    2. Garibotto V,
    3. Burkhard PR

    . 123I-FP-CIT SPECT accurately distinguishes parkinsonian from cerebellar variant of multiple system atrophy. Clin Nucl Med 2018;43:e33–36 doi:10.1097/RLU.0000000000001899 pmid:29215405

    CrossRefPubMed
27. 27.↵
    1. McKeith I,
    2. O'Brien J,
    3. Walker Z, et al

    ; DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a Phase III, multicentre study. Lancet Neurol 2007;6:305–13 doi:10.1016/S1474-4422(07)70057-1 pmid:17362834

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Thomas AJ,
    2. Attems J,
    3. Colloby SJ, et al

    . Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 2017;88:276–83 doi:10.1212/WNL.0000000000003512 pmid:27940650

    Abstract/FREE Full Text
29. 29.↵
    1. McKeith IG,
    2. Boeve BF,
    3. Dickson DW, et al

    . Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 2017;89:88–100 doi:10.1212/WNL.0000000000004058 pmid:28592453

    Abstract/FREE Full Text
30. 30.↵
    1. Lorberboym M,
    2. Treves TA,
    3. Melamed E, et al

    . [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 2006;21:510–14 doi:10.1002/mds.20748 pmid:16250023

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Felicio AC,
    2. Godeiro-Junior C,
    3. Moriyama TS, et al

    . Degenerative parkinsonism in patients with psychogenic parkinsonism: a dopamine transporter imaging study. Clin Neurol Neurosurg 2010;112:282–85 doi:10.1016/j.clineuro.2009.12.010 pmid:20061077

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Brigo F,
    2. Matinella A,
    3. Erro R, et al

    . [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson’s disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol 2014;21:1369–90 doi:10.1111/ene.12444 pmid:24779862

    CrossRefPubMed
33. 33.↵
    1. Bauckneht M,
    2. Chincarini A,
    3. De Carli F, et al

    . Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: a systematic review and meta-analysis. Sleep Med Rev 2018;41:266–74 doi:10.1016/j.smrv.2018.04.001 pmid:29784534

    CrossRefPubMed
34. 34.↵
    1. Berg D,
    2. Postuma RB,
    3. Adler CH, et al

    . MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015;30:1600–11 doi:10.1002/mds.26431 pmid:26474317

    CrossRefPubMed
35. 35.↵
    1. Takikawa S,
    2. Dhawan V,
    3. Chaly T, et al

    . Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994;35:955–63 pmid:8195882

    Abstract/FREE Full Text
36. 36.↵
    1. Sossi VD,
    2. La Fuente-Fernandez R,
    3. Holden JE, et al

    . Increase in dopamine turnover occurs early in Parkinson’s disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 2002;22:232–39 doi:10.1097/00004647-200202000-00011 pmid:11823721

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Hazut Krauthammer S,
    2. Cohen D,
    3. Even-Sapir E, et al

    . Beyond visual assessment of basal ganglia uptake: can automated method and pineal body uptake assessment improve identification of nigrostriatal dysfunction on 18F-DOPA PET/CT? Int J Mol Sci 2023;24:5683 doi:10.3390/ijms24065683 pmid:36982756

    CrossRefPubMed
38. 38.↵
    1. Dhawan V,
    2. Ma Y,
    3. Pillai V, et al

    . Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J Nucl Med 2002;43:1324–30 pmid:12368370

    Abstract/FREE Full Text
39. 39.↵
    1. Huang WS,
    2. Chiang YH,
    3. Lin JC, et al

    . Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson’s disease patients. J Nucl Med 2003;44:999–1005 pmid:12843212

    Abstract/FREE Full Text
40. 40.↵
    1. Wallert E,
    2. Letort E,
    3. van der Zant F, et al

    . Comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT acquired in clinical practice for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome. EJNMMI Res 2022;12:68 doi:10.1186/s13550-022-00943-6 pmid:36273088

    CrossRefPubMed
41. 41.↵
    1. Dhawan V,
    2. Niethammer MH,
    3. Lesser ML, et al

    . Prospective F-18 FDOPA PET imaging study in human PD. Nucl Med Mol Imaging 2022;56:147–57 doi:10.1007/s13139-022-00748-4 pmid:35607632

    CrossRefPubMed
42. 42.↵
    1. Khamis K,
    2. Giladi N,
    3. Levine C, et al

    . The added value of 18F-FDOPA PET/CT in the work-up of patients with movement disorders. Neurographics 2019;9:344–48 doi:10.3174/ng.1900004

    CrossRef
43. 43.↵
    1. Struck AF,
    2. Hall LT,
    3. Kusmirek JE, et al

    . (18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison. Am J Nucl Med Mol Imaging 2012;2:475–82 pmid:23145363

    PubMed